esmo 2022: lba4 - results from the randomized, phase 3 checkmate 914 trial
Published 1 year ago • 145 plays • Length 10:13Download video MP4
Download video MP3
Similar videos
-
2:05
esmo 2020 highlights on nivolumab cabozantinib as 1st line therapy for arcc: the checkmate 9er study
-
25:09
kidney cancer highlights from esmo 2022
-
10:51
asco gu24 special: assoc. prof. barata discusses the results of keynote-564 and checkmate-914
-
33:28
esmo 2022: highlights, commentary and analysis
-
1:38
kidney cancer research at esmo 2020: toni choueiri, md
-
9:57
how to select 1st line therapy for metastatic renal cell cancer?
-
3:30
promising results for axitinib and pembrolizumab in advanced renal cell cancer
-
5:14
promising results for nivolumab in advanced liver cancer
-
6:31
toni choueiri:
-
0:59
updates in kidney cancer at esmo 2022
-
2:56
#esmo22 highlights on cabozantinib with nivo and ipi for intermediate/poor risk adv. rcc: cosmic-313
-
0:53
first results from the checkmate 9er phase iii trial
-
4:12
kidney cancer at esmo 2022: keynote-564 and prosper
-
5:56
results from checkmate-032, nivolumab and ipilimumab for melanoma
-
![webcast with q[&]a from esmo 2022 press briefing](https://i.ytimg.com/vi/_AoR0WN9y7I/mqdefault.jpg)
23:00
webcast with q[&]a from esmo 2022 press briefing
-
3:02
checkmate 238 results presented at esmo 2017
-
4:23
esmo22: cabozantinib in combination with nivo & ipi in previously untreated arcc of imdc interme...
-
3:10
esmo22 - first results of the radicals-hd trial (isrctn40814031)
-
3:09
#esmo21 highlights on nivo ipi vs extreme in 1st-line high-risk scchn: the checkmate 651 study
-
3:59
checkmate 067 - combined nivolumab and ipilimumab
-
1:43
rcc data at esmo 2020
-
5:06
phase 3 checkmate - 214